Drug Trial Radar · NCT05287503
Ambroxol as a Disease-modifying Treatment in GBA-PD
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Mar 9, 2022
Primary completion
Dec 15, 2024
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- IRCCS National Neurological Institute "C. Mondino" Foundation; University of Campania Luigi Vanvitelli
- First posted
- Mar 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present multicenter, randomized, double-blind, placebo-controlled clinical trial will investigate whether the prolonged administration of high-dose oral Ambroxol over 52 weeks is safe, tolerable, able to change Glucocerebrosidase enzyme activity and alpha-synuclein levels in the central nervous system and, ultimately, to reduce the progression of cognitive decline and motor disability in 60 individuals with Parkinson's disease with mutations of the glucocerebrosidase gene (GBA1; OMIM 606463). Participants will undergo clinical, biomarker blood and cerebrospinal fluid analysis, neuropsychological, neuroimaging assessment throughout the course of the study.
Conditions
- Parkinson Disease
- GBA Gene Mutation
Interventions
Ambroxol HydrochlorideDrug
Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.
PlaceboDrug
Excipients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Montreal Cognitive Assessment scoreTime frame: baseline and week 52
- Change from baseline in conversion rate from normal cognitive function (PD-N) to mild cognitive impairment (PD-MCI) and from PD-N or PD-MCI to Parkinson-Dementia (PD-D)Time frame: baseline and week 52
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
University of Campania "Luigi Vanvitelli"
Naples, Italy
IRCCS National Neurological Institute "C. Mondino" Foundation
Pavia, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.